Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study

Abstract

Multiple myeloma (MM) is a plasmocytic malignancy which accounts for approximately 10% of all hematologic malignancies. In 2016, over 16,500 new cases were diagnosed in China, and approximately 10,300 patients died of the disease. [1] In novel-agent era, some patients had a poor prognosis with a median overall survival (OS) of <2 years although they received the therapy regimen containing novel agents and autologous peripheral blood stem cell transplantation (APBSCT) as front-line therapy.

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients

“…Despite this heterogeneity, results are highly consistent with recent findings from clinical trials 1 and support the utility of SoC comprehensive genetic profiling at diagnosis, including as a minimum t(4;14), t(14;16)/t(14;20), gain(1q) and del(17p), for early identification of high‐risk patients. These results are in keeping with other recently published findings 8–10 . With an expected increase in choice regarding treatment intensity for NDMM patients, appropriate diagnostics at baseline are likely to emerge as essential tools particularly for risk‐adapted consolidation and maintenance strategies 6 .…”

“…These results are in keeping with other recently published findings. [8][9][10] With an expected increase in choice regarding treatment intensity for NDMM patients, appropriate diagnostics at baseline are likely to emerge as essential tools particularly for risk-adapted consolidation and maintenance strategies. 6 Although introduction of quadruplet Dara-VTD induction as SoC is likely to improve initial response rates of patients with double hit NDMM, recent analyses from MASTER, FORTE, and UK OPTIMUM/MUKnine trials suggest in particular risk-adapted post-ASCT treatment intensification is highly important for this patient group.…”